Physician profile
Roberto R Monarez
NPI 1396073037
$467.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $121.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $102.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.73 | 2019-2020 | |
| Allergan, INC. | $74.56 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $48.41 | 2019-2020 | |
| Chiesi USA, INC. | $47.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.54 | 2019 | |
| Abbott Laboratories | $17.10 | 2019 | |
| Medtronic Vascular, INC. | $12.62 | 2019 | |
| Glaxosmithkline, LLC. | $12.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.81 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Monarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.